Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 5, 2011, Pages 369-373

  Ben Hadj Khalifa, Sonia ^a,b   Hézard, Nathalie ^b,c   Almawi, Wassim Y ^d   Remy, Marie G ^b   Florent, Bernadette ^b   Mahjoub, Touhami ^a   Nguyen, Philippe ^b,c  

^a Unité de Recherche des Maladies Hématologiques et Auto Immunes   (Tunisia)

^b SERVICE DE DERMATOLOGIE   (France)

^c Reims University Hospital   (France)

^d ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

enoxaparin; fondaparinux; monocyte; monocyte derived microparticle; thrombin generation; unfractionated heparin

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; LIPOPOLYSACCHARIDE;

ADULT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; IN VITRO STUDY; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBIN TIME;

EID: 85027951577     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328344f7d0     Document Type: Article

References (24)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 33:141-159
2. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the antifactor Xa and antifactor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5:955-962 (Pubitemid 46691725)
3. Petros S, Siegemund T, Siegemund A, Engelmann L. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis 2006; 17:131-137
4. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 2009; 59:160-166
5. Poitevin S, Cochery-Nouvellon E, Dupont A, Nguyen P. Monocyte IL-10 produced in response to lipopolysaccharide modulates thrombin generation by inhibiting tissue factor expression and release of active tissue factor-bound microparticles. Thromb Haemost 2007; 97:598-607 (Pubitemid 46592938)
6. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111:2654-2661 (Pubitemid 40740866)
7. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91:146-154 (Pubitemid 38111231)
8. Leatham EW, Bath PM, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 1995; 73:10-13
9. Leroyer AS, Isobe H, Lesèche G, Castier Y, Wassef M, Mallat Z, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49:772-777 (Pubitemid 46240708)
10. Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Heamost 2008; 100:878-885
11. Barstad RM, Hamers MJ, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIdependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol 1995;15:11-16
12. Ardissino D, Merlini PA, Ariëns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769-771 (Pubitemid 27122461)
13. Ott I, Andrassy M, Zieglgänsberger D, Geith S, Schömig A, Neumann FJ. Regulation of monocyte procoagulant activity in acute myocardial infraction: role of tissue factor and tissue factor pathway inhibitor-1 Blood 2001; 97:3721-3726
14. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99:2794-2800 (Pubitemid 34525367)
15. Nguyen P, Broussas M, Cornillet-Lefebvre P, Potron G. Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide. Transfusion 1999; 39:975-982 (Pubitemid 29439794)
16. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32:249-253 (Pubitemid 37490547)
17. Ben-Hadj-khalifa-Kechiche S, Hezard N, Poitevin S, Remy MG, Florent B, Mahjoub T, et al. Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles. J Thromb Thrombolysis 2010; 30:412-418
18. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwège V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 53:3245-3255 (Pubitemid 24292551)
19. Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99:348-353 (Pubitemid 29051259)
20. Al Dieri R, Wagenvoord R, van Dedem GW, Bèguin S, Hemker HC. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain. J Thromb Haemost 2003; 1:907-914
21. Elgue G, Sanchez J, Egberg N, Olsson P. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation. Thromb Res 1994; 75:539-549 (Pubitemid 24267337)
22. Anderson JA, Hirsh J, Yusuf S, Johnston M, Afzal R, Mehta SR, et al.Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organisation to assess strategies in acute ischemic syndromes (OASIS)-5 trial. J Thromb Haemost 2010; 8:243-249
23. Michelangelo OASIS 5 Steering Committee, Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST segment elevation acute coronary syndromes. Am Heart J 2005; 150:1107
24. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43:2183-2190 (Pubitemid 38757583)